Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Interest Expenses (2016 - 2025)

Historic Interest Expenses for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $2.6 million.

  • Northwest Biotherapeutics' Interest Expenses rose 2600.96% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 3091.55%. This contributed to the annual value of $7.8 million for FY2024, which is 4819.69% up from last year.
  • Northwest Biotherapeutics' Interest Expenses amounted to $2.6 million in Q3 2025, which was up 2600.96% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Interest Expenses ranged from a high of $2.6 million in Q3 2025 and a low of $807000.0 during Q2 2021
  • Moreover, its 5-year median value for Interest Expenses was $1.5 million (2024), whereas its average is $1.6 million.
  • Data for Northwest Biotherapeutics' Interest Expenses shows a peak YoY increase of 13152.0% (in 2021) and a maximum YoY decrease of 7104.69% (in 2021) over the last 5 years.
  • Over the past 5 years, Northwest Biotherapeutics' Interest Expenses (Quarter) stood at $1.2 million in 2021, then increased by 5.9% to $1.2 million in 2022, then grew by 1.72% to $1.2 million in 2023, then surged by 100.32% to $2.5 million in 2024, then rose by 5.35% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $1.8 million for Q2 2025, and $1.6 million during Q1 2025.